COSMO PHARMACEUT. EO-,26/ NL0011832936 /
| 2024-04-25 2:45:02 PM | Chg. -1.5000 | Volume | Bid5:35:36 PM | Ask5:35:36 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 74.5000EUR | -1.97% | 0 Turnover: 0.0000 |
-Bid Size: - | -Ask Size: - | 1.2 bill.EUR | 2.72% | 1,037.06 |
Assets
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 30.2000 | 29.3000 | 30.4800 | 30.2800 | 28.5880 | ||||||
| Intangible Assets | 49.2000 | 26.6000 | 372.7300 | 366.3900 | 368.9930 | ||||||
| Long-Term Investments | 53.9000 | 114.5000 | 49.0800 | 8.2700 | 3.2860 | ||||||
| Fixed Assets | 282.8000 | 343.3000 | 529.7100 | 453.5000 | 451.7540 | ||||||
| Inventories | 6.1000 | 5.7000 | 13.1200 | 11.5000 | 14.1980 | ||||||
| Accounts Receivable | 16.5000 | 23 | 20.5100 | 34.0800 | 28.4540 | ||||||
| Cash and Cash Equivalents | 110.4000 | 185.9000 | 198.5600 | 185.8300 | 50.2750 | ||||||
| Current Assets | 302.4000 | 252.9000 | 275.8500 | 306.1000 | 102.2260 | ||||||
| Total Assets | 585.2000 | 596.2000 | 805.5600 | 759.5900 | 553.9800 | ||||||
Liabilities
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 7.8000 | 8.4000 | 11.5900 | 1,066 | 11.5600 | ||||||
| Long-term debt | 163.3000 | 165.2000 | 169.0300 | 1.7700 | .9420 | ||||||
| Liabilities to Banks | 164.8000 | 168.1000 | - | - | - | ||||||
| Provisions | 8.8000 | 6.3000 | - | - | 95.0930 | ||||||
| Liabilities | 191.4000 | 196 | 292.8800 | 295.8000 | 120.3460 | ||||||
| Share Capital | 3.9000 | 3.9100 | - | - | 4.5620 | ||||||
| Total Equity | 393.7000 | 400.1000 | 505.2800 | 456.9300 | 426.7580 | ||||||
| Minority Interests | 0.0000 | 0.0000 | 7.4000 | 6.8600 | 6.8760 | ||||||
| Total liabilities equity | 585.2000 | 596.2000 | 805.5600 | 759.5900 | 553.9800 | ||||||
Income Statement
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 62.5000 | 60.9000 | 65.0700 | 102.1000 | 96.7230 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | -12.3000 | 6.9000 | 11.1000 | 28.0600 | 12.2260 | ||||||
| Interest Income | - | - | -4.2900 | -3.5800 | -4.6150 | ||||||
| Income Before Taxes | -21.2200 | -6.9000 | - | - | - | ||||||
| Income Taxes | -3.2000 | -1 | 2.3300 | 6.9700 | 6.2640 | ||||||
| Minority Interests Profit | 0.0000 | 0.0000 | 1 | 280 | .2000 | ||||||
| Net Income | -24.4000 | -7.9000 | 21.6700 | 17.2300 | 1.1470 | ||||||
Per Share
Cash Flow
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -17.6000 | 10.1000 | 15.2000 | 35.1800 | 37.6030 | ||||||
| Cash Flow from Investing Activities | -48.7000 | 75.4000 | 24.8600 | 1.6900 | 40.3030 | ||||||
| Cash Flow from Financing | -34.5000 | -11.9000 | -27.2500 | -4,613 | -209.2660 | ||||||
| Decrease / Increase in Cash | -102 | 76.5000 | - | - | - | ||||||
| Employees | 234 | 265 | 290 | 293 | 310 | ||||||
